Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.
Published:
Best FDA-Approved GLP-1 on MedImpact Formulary: Your 2026 Coverage Decoder
By The RX Index Editorial Team · Last verified: May 23, 2026
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. This page is a coverage guide, not medical advice.
Here’s the short answer for the best FDA-approved GLP-1 on MedImpact formulary in 2026: Mounjaro, Ozempic, Rybelsus, and Trulicity are preferred-brand GLP-1s for type 2 diabetes. For weight loss, Wegovy and Zepbound are listed as preferred brand — but your specific employer plan has to have opted into anti-obesity coverage. Some plans haven’t. That gap is where people get blindsided.
You’re staring at your insurance card. It says MedImpact. Your doctor wants to write you a GLP-1 prescription. And nobody — not your pharmacy, not your HR rep, not even your doctor — can give you a straight answer about what’s actually covered.
We’ve decoded the public MedImpact MedPerform Premier formulary documents so you don’t have to.
What we actually verified (so you can trust this page):
Safety check before any GLP-1 path
Not everyone is a candidate for GLP-1 treatment. Ask your prescriber about personal or family history of medullary thyroid carcinoma or MEN2, pancreatitis, gallbladder disease, kidney problems, severe GI disease, pregnancy or planned pregnancy, diabetes medication interactions, and whether you should avoid combining GLP-1 drugs. Your prescriber decides what’s safe for your body. This page decides what’s covered.
The MedImpact FDA-Approved GLP-1 Decoder Matrix
Every FDA-approved GLP-1, mapped to its current MedImpact public formulary status, the exact PA and quantity-limit notes, what it’s covered for, and your cash-pay fallback if you get denied.
| Medication | Active Ingredient | MedImpact Status | Indication | Exact Restrictions (Jan 2026) | Best For | Cash-Pay Fallback |
|---|---|---|---|---|---|---|
| Mounjaro | tirzepatide | Preferred Brand | Type 2 Diabetes | Tier 2; PA; diagnosis code required; QL 0.5 mL per 7 days | T2D + secondary weight loss benefit | List price $1,112.16/fill before coverage; actual cost depends on plan and savings |
| Ozempic | semaglutide | Preferred Brand | Type 2 Diabetes | Tier 2; PA; diagnosis code required; QL 3 mL per 28 days | T2D + cardiovascular risk reduction | $199/mo first 2 months for eligible new self-pay (lower doses), then $349–$499/mo |
| Trulicity | dulaglutide | Preferred Brand | Type 2 Diabetes | Tier 2; PA; diagnosis code required; QL 2 mL per 28 days | T2D + CV risk reduction; easier-to-use pen | Manufacturer savings programs; insurance-routed |
| Rybelsus | oral semaglutide | Preferred Brand | Type 2 Diabetes | Tier 2; PA; diagnosis code required; QL 1 tablet per day | Needle-averse T2D patients | List price $997.58/package; manufacturer savings for eligible commercial coverage |
| Wegovy (pen) | semaglutide | Preferred Brand (if covered) | Chronic Weight Management | Tier 2 under Anti-Obesity Agents (Jan) / Weight Reduction (April PDL); PA, QL; plan opt-in required | Weight loss when plan covers it; CVD risk reduction with established CVD | $199/mo first 2 months, then $349/mo via NovoCare |
| Wegovy Pill | oral semaglutide | Not on Jan/April 2026 PDL | Chronic Weight Management | Formulary exception likely required | Needle-averse weight management | $149/mo for 1.5 mg and 4 mg; $299/mo for 9 mg and 25 mg |
| Wegovy HD (7.2mg) | semaglutide | Not on Jan/April 2026 PDL | Chronic Weight Management | Formulary exception likely required; new drug | Plateau on Wegovy 2.4 mg | $399/mo self-pay |
| Zepbound (pen/KwikPen) | tirzepatide | Preferred Brand (if covered) | Chronic Weight Management | Tier 2 under Anti-Obesity Agents (Jan) / Weight Reduction (April); PA, QL; plan opt-in required | Strong weight-loss data; FDA-approved OSA indication | $299 (2.5 mg), $398 (5 mg), $499 (7.5 mg), $698 (10/12.5/15 mg) via Sesame |
| Zepbound (vials) | tirzepatide | Same as KwikPen | Chronic Weight Management | Same as KwikPen | Lower cash-pay entry point | $299/mo (2.5 mg), $399/mo (5 mg) via LillyDirect or Ro |
| Foundayo | orforglipron | Not on Jan/April 2026 PDL | Chronic Weight Management | Formulary exception likely required; new drug (FDA-approved April 1, 2026) | Daily pill, no fasting rules | $149 (0.8 mg), $199 (2.5 mg), $299 (5.5/9 mg), $349 (14.5/17.2 mg) via Ro / LillyDirect / Sesame |
| Saxenda | liraglutide | Generic liraglutide listed in Weight Reduction | Chronic Weight Management | Tier 1 with PA; BMI criteria | Daily injection, step-therapy requirement path | Generic liraglutide at pharmacy |
| Generic exenatide | exenatide | Tier 1 | Type 2 Diabetes | Tier 1; PA; diagnosis code required; QL | T2D cheaper option | Generic at pharmacy |
| Byetta / Bydureon / Adlyxin | exenatide / lixisenatide | Not verified as preferred | — | Standard formulary directs to alternatives | — | Switch to preferred brand or generic exenatide |
Sources: MedImpact MedPerform Premier Standard Formulary (January 2026) and MedImpact MedPerform Premier PDL update (April 1, 2026). Pricing verified May 2026 via Ro, LillyDirect, NovoCare, and Sesame Care. PA, QL, and Step Therapy flags taken directly from the public MedImpact January 2026 formulary; your specific plan’s restrictions may vary.
Common terms decoded
Want help turning this matrix into an actual approved prescription? Ro’s Insurance Concierge handles the PA submission and follow-up for MedImpact commercial members.
See if Ro’s Insurance Concierge handles your MedImpact plan → (sponsored affiliate link, opens in a new tab)(sponsored)Quick Answer: What Is the Best FDA-Approved GLP-1 on MedImpact Formulary?
For type 2 diabetes, the preferred-brand GLP-1s on MedImpact’s public formulary are Mounjaro, Ozempic, Rybelsus, and Trulicity — all Tier 2 with prior authorization and diagnosis-code requirements. For weight management, Wegovy and Zepbound are listed as preferred brand in the anti-obesity category, but coverage depends on whether your employer plan opted into anti-obesity drugs. New drugs Foundayo and Wegovy HD aren’t yet on the public January or April 2026 formularies.
If you want one provider that handles the prior authorization paperwork for you:
Ro Body (sponsored affiliate link, opens in a new tab) is the cleanest path for commercial MedImpact members. Their Insurance Concierge gathers coverage information, submits PA paperwork, goes back and forth with insurance, and explores alternatives or cash-pay if coverage fails. Membership starts at $39 for the first month, then $149/month — or as low as $74/month with annual prepay. Medication is billed through your MedImpact pharmacy benefit at your standard copay if approved.
Note: Ro cannot coordinate GLP-1 insurance coverage for government insurance. Medicaid members cannot join Ro Body. Medicare, Medicare supplement, and TRICARE members can join and pay out of pocket for cash-pay options but Ro won’t pursue government coverage. FEHB members can join and access the Insurance Concierge.
Check eligibility on Ro Body → (sponsored affiliate link, opens in a new tab)(sponsored)Does MedImpact Cover Wegovy?
Wegovy is listed as a preferred brand under MedImpact’s anti-obesity category (Anti-Obesity Agents in the January 2026 full formulary; Weight Reduction in the April 2026 PDL). Whether your specific plan actually covers it depends on whether your employer opted into anti-obesity drug coverage.
The same drug can be listed in two places: the full Standard Formulary uses the category name Anti-Obesity Agents, while the public PDL uses Weight Reduction. Either way, the practical question is the same — did your employer add the weight-management benefit?
The “if covered” rule, in plain English
The MedImpact PDL has a section that says “Weight Reduction (if covered).” Under it, Wegovy and Zepbound are listed as preferred brand. Contrave and Plenity are listed as excluded. That phrase “if covered” is the whole story. If your employer didn’t opt in, none of this applies to you. You’ll pay cash or switch paths.
If your employer did opt in, expect a prior authorization with BMI documentation and a history of lifestyle attempts. If they didn’t, you’ll either pay cash or look at MedImpact’s new GLP-1 Direct Fund program (covered below).
Does MedImpact Cover Zepbound?
Zepbound is also listed as a preferred brand under MedImpact’s anti-obesity category in both the January 2026 full formulary and the April 2026 PDL. Coverage depends on whether your specific plan opted into anti-obesity drug coverage. If covered, expect prior authorization with BMI of 30 or higher (or 27+ with a weight-related condition like high blood pressure, type 2 diabetes, or sleep apnea).
Zepbound’s OSA indication
Zepbound has a second FDA-approved indication: moderate-to-severe obstructive sleep apnea in adults with obesity. If your prescriber is documenting OSA, that’s a separate path that some plans will cover even when general obesity coverage is restricted.
“Listed” Does Not Always Mean “Covered” — Here’s What That Means
The MedImpact formulary you’re reading is a default. Your actual coverage is decided by your specific plan sponsor — usually your employer. MedImpact administers the benefit. Your employer decides what’s actually covered. The standard formulary is a starting point. Your employer’s HR team picks the actual coverage rules on top of it.
That’s why two people with the same MedImpact card can get totally different answers about whether Wegovy is covered. One person’s employer added the weight-loss rider. The other’s didn’t.
Scenario 1: You search "Zepbound" in the MedImpact portal and it shows Tier 2.
Looks great. Then your pharmacy claim gets rejected because your plan excludes anti-obesity drugs.
Scenario 2: You see “PA required.”
That means even if your plan covers it, you can’t get it filled until your doctor submits paperwork and MedImpact approves it.
Scenario 3: You see “Step Therapy required.”
Your plan wants you to try one drug before another. Skipping that step gets you denied.
Most of these blocks can be solved. They just need to be solved in the right order.
Rather not fight the paperwork yourself? Ro’s Insurance Concierge handles the PA submission and follow-up for commercial MedImpact members.
Check eligibility on Ro Body → (sponsored affiliate link, opens in a new tab)Why Does MedImpact Show Tier 2 But Still Deny the Claim?
Tier and copay are only one piece of the coverage picture. A drug can show Tier 2 in your portal and still be denied because of prior authorization criteria, diagnosis mismatch, quantity limits, pharmacy network requirements, or benefit exclusions. Match your MedImpact portal status to the right next step:
| What your portal shows | What it means | Ask member services | Ask your prescriber | When Ro or Sesame fits |
|---|---|---|---|---|
| Tier 2, no PA flag | Likely covered with normal copay | “Is there a network pharmacy requirement?” | “Send the script to my preferred pharmacy” | If you don’t have a prescriber yet |
| Tier 2, PA required | Covered if your doctor’s PA gets approved | “What PA criteria apply for my diagnosis?” | “Submit PA with the exact MedImpact criteria” | If you want someone else to handle the PA |
| QL flag | Quantity capped per refill | “What’s the QL for this dose?” | “Match the dose and refill schedule to the QL” | If your dose escalates and you keep hitting the QL |
| ST (Step Therapy) | Try cheaper drug first | “Which drugs satisfy step therapy?” | “Document the prior trial or contraindication” | If you’ve already tried alternatives and have records |
| Not covered / Excluded | Plan excludes this drug or category | “Is this a benefit exclusion or non-formulary?” | “Can we request a formulary exception?” | If exception fails, cash-pay through Ro, Sesame, or LillyDirect/NovoCare |
| Specialty pharmacy required | Must use specific pharmacy | “Which specialty pharmacy?” | “Send the script to the required pharmacy” | If your plan requires Birdi mail-order and you want telehealth in parallel |
| Birdi mail-order required | MedImpact’s mail-order pharmacy | “What’s the refill workflow?” | “Send to Birdi with right refill cadence” | Less relevant — Birdi is the dispensing pipeline |
Does MedImpact Cover GLP-1s for Weight Loss?
It depends on your specific employer plan. The standard MedImpact MedPerform Premier formulary lists anti-obesity drugs as a general exclusion example — meaning they’re excluded by default unless the employer opts in. When an employer does opt in, Wegovy and Zepbound show up as preferred-brand options.
How to find out if YOUR plan opted in (the 3-minute version)
- Pull up your insurance card. Confirm MedImpact is your PBM.
- Log into your MedImpact member portal or download the app.
- Search “Wegovy” and “Zepbound.”
- If you see a tier and copay estimate, that’s a strong signal your plan opted in — but still confirm PA, diagnosis, quantity limit, and pharmacy rules before assuming the claim will pay.
- If you see "Not covered" or "Excluded," your plan didn’t opt in.
- To confirm anything unclear, call the member services number on the back of the card.
MedImpact’s new GLP-1 Benefit 360 and GLP-1 Direct Fund (launched March 2026)
In March 2026, MedImpact announced two new options for employers who want to cover GLP-1s without cost spiraling:
GLP-1 Benefit 360
A structured covered benefit. Plan and member spending are both capped. Pricing is the same across all dose strengths. Members also get the MedEmpower Fuel app and registered dietitian coaching included. If your employer adopted this in 2026, your coverage path is simpler and your monthly cost won’t jump when you titrate up.
GLP-1 Direct Fund
Your employer contributes a fixed dollar amount toward direct-to-consumer pricing (like LillyDirect, NovoCare, or Ro). This is for plans that don’t offer a traditional benefit but still want to help offset cash-pay costs.
Ask your HR team or member services rep: “Does my plan participate in GLP-1 Benefit 360 or GLP-1 Direct Fund?” If yes, your math just got noticeably better.
Plan covers obesity drugs? Let Ro’s Insurance Concierge pursue your PA. Plan doesn’t? Take our 60-second matching quiz to see your best cash-pay path.
How MedImpact’s Prior Authorization Works for GLP-1s
Prior authorization is the paperwork your doctor sends to MedImpact before your plan agrees to pay. For T2D GLP-1s, your doctor documents the T2D diagnosis and recent A1C. For weight-management GLP-1s when covered, your doctor documents BMI of 30 or higher (or 27+ with a weight-related condition) plus a history of lifestyle attempts. Ro says its GLP-1 insurance and PA process usually takes about 2–3 weeks.
The PA process, step by step
- 1Your doctor writes the prescription.
- 2Your pharmacy submits the claim and gets a “PA required” rejection.
- 3Your doctor’s office submits the PA form to MedImpact with supporting documents.
- 4MedImpact reviews against the plan’s clinical criteria.
- 5You get either approval (usually good for 6–12 months) or denial with a written reason.
- 6If denied, you have three paths: fix the documentation, appeal, or request a formulary exception.
The three types of denials (and what each one actually means)
| Denial type | What it means | What to do next |
|---|---|---|
| Missing clinical documentation | Your doctor didn’t include something required (A1C, BMI, prior medication trial, comorbidity) | Ask your doctor to resubmit with the missing items |
| Non-formulary | The drug isn’t on your plan’s covered list | Request a formulary exception OR switch to a preferred-brand alternative |
| Benefit exclusion | Your plan excludes the category entirely (e.g., no anti-obesity drugs) | Appeal is usually a long shot. Look at cash-pay options or wait for HR to change the benefit |
If your doctor’s office tells you “you got denied” — that’s not enough information. Ask them: “Which of those three types is it?” Then act based on the answer.
The most common PA mistakes — and how to avoid them
- ✕Wrong indication on the form. Asking for Ozempic for weight loss → instant denial. Ozempic is approved for type 2 diabetes and CV risk reduction. If you don’t have T2D, your doctor shouldn’t be writing Ozempic.
- ✕No metformin trial documented. If your plan requires step therapy through metformin first, the chart needs to show you tried metformin (or that you can’t take it). If it’s not in writing, the PA fails.
- ✕BMI on file is just under the threshold. Most weight-loss GLP-1 PAs need BMI ≥30, or ≥27 with a comorbidity. Have your weight rechecked at the appointment.
- ✕Asking for Zepbound on a plan that prefers Wegovy. Some plans require step therapy through one weight-loss GLP-1 before approving the other.
The honest part
Even when everything is done right, a GLP-1 PA can still get denied on the first pass. If the denial is about missing documentation or another eligible GLP-1, it’s fixable. If it’s a true benefit exclusion, that’s the brutal one. If you’d rather hand the paperwork off, that’s where Ro’s Insurance Concierge comes in.
Commercial MedImpact + want someone to handle the paperwork? Check Ro eligibility → (sponsored affiliate link, opens in a new tab)$39 first month, then $149/month or as low as $74/month with annual prepay. Medication billed through your MedImpact benefit at your standard copay if approved. (sponsored)
What You’ll Actually Pay With MedImpact
If your MedImpact plan covers your GLP-1 and PA is approved, your copay depends entirely on your plan’s benefit design — check your member portal or call member services for the exact number.
Manufacturer savings cards (the fine print)
Manufacturer savings cards have rules. They generally require commercial insurance, exclude government insurance, set maximum savings limits, and expire on program-specific dates. The Foundayo Savings Card, for example, is valid through December 31, 2026. Always read the current terms on the manufacturer site before relying on any “as low as $25/month” claim.
Cash-pay fallback prices (verified May 2026)
| Drug | Source | Verified price |
|---|---|---|
| Wegovy pen | NovoCare | $199/mo first 2 months, then $349/mo (standard doses) |
| Wegovy pill | NovoCare / Ro / Sesame | $149/mo for 1.5 mg and 4 mg; $299/mo for 9 mg and 25 mg |
| Wegovy HD (7.2 mg) | NovoCare | $399/mo |
| Zepbound KwikPen | Sesame | $299 (2.5 mg), $398 (5 mg), $499 (7.5 mg), $698 (10/12.5/15 mg) |
| Zepbound vials | LillyDirect / Ro | $299/mo (2.5 mg), $399/mo (5 mg) |
| Foundayo (orforglipron) | Ro / LillyDirect / Sesame | $149 (0.8 mg), $199 (2.5 mg), $299 (5.5/9 mg), $349 (14.5/17.2 mg) |
| Mounjaro | LillyDirect / pharmacy | List price $1,112.16/fill before coverage; actual cost depends on plan and savings |
| Ozempic | NovoCare / Sesame | $199/mo first 2 months for eligible new self-pay (lower doses); $349–$499/mo afterward |
| Rybelsus | NovoCare / pharmacy | List price $997.58/package; manufacturer savings for eligible commercial coverage |
Ro matches LillyDirect, NovoCare, and TrumpRx pricing on the medication itself. The Ro Body membership fee is on top of that and pays for clinician visits, coaching, and Insurance Concierge work.
Want to see what you’d pay through Ro with your specific plan?
See current Ro pricing and eligibility → (sponsored affiliate link, opens in a new tab)The Best FDA-Approved GLP-1 on MedImpact — By Your Specific Situation
“Best” depends on three things: your indication (diabetes or weight management), whether your plan opted into obesity coverage, and what you’ve tried before.
If you have type 2 diabetes (most common situation)
Best ask: Mounjaro. Preferred brand on MedImpact for T2D. The dual GLP-1/GIP mechanism produced strong A1C and weight-loss outcomes in the SURPASS trials.
Choose Ozempic or Trulicity if cardiovascular-risk labeling is part of your prescriber’s decision. Ozempic is FDA-approved to reduce major adverse cardiovascular events (MACE) in adults with T2D and established CVD. Trulicity is FDA-approved to reduce MACE in adults with T2D who have either established CVD or multiple CV risk factors.
Choose Rybelsus if: you cannot tolerate injections. It’s an oral pill taken daily. The tradeoff: strict fasting rules — take it on an empty stomach with a small sip of water, wait 30 minutes before eating, drinking, or taking other medications.
If your plan opted into obesity coverage and you want weight loss
Best ask: Zepbound. Preferred brand under MedImpact’s anti-obesity category. Strong weight-loss trial data, and FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity.
Choose Wegovy instead if: you have established cardiovascular disease plus overweight or obesity. Wegovy has an FDA-approved indication to reduce cardiovascular death, heart attack, and stroke risk in this population — a benefit Zepbound doesn’t share yet.
If your plan did NOT opt into obesity coverage
You have four paths:
- Appeal or request a formulary exception. Long shot if it’s a benefit exclusion, better odds if it’s a clinical-criteria denial.
- Use the cash-pay option. Ro or NovoCare for Wegovy ($199/mo first two months, then $349/mo). LillyDirect or Ro for Zepbound vials ($299–$399/mo). Sesame for Zepbound KwikPen across dose levels.
- See if your HR team will add weight-loss coverage at open enrollment. Worth asking, especially with MedImpact’s new GLP-1 Benefit 360 program available to employers in 2026.
- Take our 60-second matching quiz to see which path fits your budget and timeline.
If you’ve already tried a GLP-1 and plateaued
For Wegovy 2.4mg plateau: Ask about Wegovy HD (7.2mg). FDA-approved March 19, 2026 for adults who tolerated the 2.4mg dose for at least 4 weeks and need more weight reduction. Not yet on MedImpact’s public January or April 2026 formularies, so expect a formulary exception or self-pay ($399/mo) until your plan updates.
Alternative: Switch from semaglutide to tirzepatide (Zepbound) for the dual-receptor mechanism. Common move when semaglutide stalls.
If you want a daily oral GLP-1 (no injections)
Best ask: Foundayo (orforglipron). FDA-approved April 1, 2026. First small-molecule, non-peptide oral GLP-1 for weight management. Take it once daily, any time, with or without food, with no water restrictions.
Rybelsus and Wegovy pill are both oral semaglutide — but they require strict fasting rules. Foundayo doesn’t.
Foundayo isn’t on the public MedImpact January or April 2026 formularies. Expect to file a formulary exception, use the Foundayo Savings Card (valid through December 31, 2026), or self-pay through LillyDirect, Ro, or Sesame ($149–$349/month depending on dose).
If you’re on Medicare Part D, the CMS Medicare GLP-1 Bridge begins July 1, 2026 and may allow eligible beneficiaries to access certain GLP-1 medications at a $50 monthly supply. Verify through CMS as the program launches.
Still not sure which segment fits you? Take our free 60-second matching quiz — we’ll route you to your best FDA-approved option with the exact next step.
Start the 60-second match →The Doctor-Visit Script That Prevents a Rejected GLP-1 Prescription
The most common reason MedImpact denies a GLP-1 prior authorization isn’t a missing criterion — it’s the wrong drug picked for the wrong indication on the PA form. Print this and bring it to your appointment.
Print this and bring it to your appointment
“I have pharmacy benefits managed by MedImpact. According to MedImpact’s public formulary, the preferred-brand GLP-1s are Mounjaro, Ozempic, Rybelsus, and Trulicity for type 2 diabetes (Tier 2 with PA and quantity limits), and Wegovy and Zepbound for weight management IF my plan covers anti-obesity drugs.
Before you write the prescription, can we confirm:
- The indication on the PA form matches what’s required — confirmed T2D with my current A1C, or my current BMI plus any weight-related conditions?
- The PA includes all supporting documentation — chart notes, prior medication trials including metformin if relevant, BMI documentation, and a medical necessity statement?
- The pharmacy you’re sending this to is in MedImpact’s network (and is the correct specialty pharmacy or Birdi mail-order if my plan requires one)?
If my first-choice drug is denied, I’d like to know in advance which alternative on MedImpact’s preferred list you’d switch me to, and whether a formulary exception is worth pursuing for my first choice.”
The MedImpact phone script — for when you call member services
“Hi. I’m a MedImpact member calling to verify coverage for a GLP-1 medication before my doctor writes the prescription. I want to confirm:
- Is [drug name] covered on my plan’s formulary for [diagnosis: type 2 diabetes / chronic weight management / cardiovascular risk reduction / obstructive sleep apnea]?
- What tier is it on, and what’s my estimated copay?
- What prior authorization criteria apply?
- Is step therapy required, and which drugs would I need to try first?
- Are there quantity limits?
- Does my plan participate in GLP-1 Benefit 360 or GLP-1 Direct Fund?
- Is my preferred pharmacy in-network for this drug, or is a specialty pharmacy or Birdi mail-order required?
- If my doctor wants to prescribe a drug that isn’t on the formulary, what’s the formulary exception process?
”
Write down the rep’s name, the date, and the reference number for the call. Follow up by sending a message through the member portal so it’s in writing.
What NOT to ask your doctor for
- ✕Don’t ask your doctor to write the wrong diagnosis to get a drug covered. That can create insurance and legal problems.
- ✕Don’t ask for Ozempic or Mounjaro for weight loss if you don’t have type 2 diabetes. You want Wegovy or Zepbound for weight management.
- ✕Don’t ask to combine two GLP-1s. Concomitant use of GLP-1 receptor agonists isn’t recommended on FDA labels.
- ✕Don’t ask your doctor to skip step therapy just because you saw the drug listed on the formulary. The PA will fail.
Is Foundayo on the MedImpact Formulary?
No — at least not on the public January 2026 MedImpact MedPerform Premier Standard Formulary or the April 2026 PDL we reviewed. Foundayo (orforglipron) was FDA-approved on April 1, 2026, and most PBMs add new GLP-1 approvals during quarterly formulary refreshes. Until your plan adds it, your three options are: formulary exception, manufacturer self-pay ($149–$349/mo depending on dose), or the Foundayo Savings Card with qualifying commercial insurance (valid through December 31, 2026).
Why Foundayo matters
Foundayo is the first small-molecule, non-peptide oral GLP-1 for weight management. It’s a daily pill you can take any time of day, with or without food, with no water restriction. Rybelsus and the Wegovy pill — both oral semaglutide — require taking the pill on an empty stomach with a small sip of water and waiting 30 minutes before anything else. Foundayo doesn’t.
How to check if your plan added it
- Search “Foundayo” or “orforglipron” in your MedImpact portal.
- If you don’t see it, call member services: “Has MedImpact added Foundayo (orforglipron) to my plan’s formulary? If not, what’s the formulary exception process?”
- If your plan adds it mid-year, expect similar PA requirements to Wegovy and Zepbound (BMI, comorbidity, lifestyle modification history).
Ro carries Foundayo. So does Sesame Care. Ro is the cleaner default for MedImpact members who want help with PA AND a cash-pay backup in one workflow. Sesame is a strong second choice if you want to pick your specific clinician.
Want to see whether Foundayo is available as a cash-pay FDA-approved option while MedImpact coverage catches up?
See current Foundayo pricing on Ro → (sponsored affiliate link, opens in a new tab)What About Wegovy HD (the New 7.2 mg Dose)?
Wegovy HD is the higher-dose version of semaglutide for weight management, FDA-approved on March 19, 2026 and launched in April 2026. It’s the highest FDA-approved GLP-1 dose for chronic weight management. Not yet on the public January or April 2026 MedImpact formularies, so coverage follows the same path as Foundayo — formulary exception or self-pay until your plan updates. Self-pay is $399/month via NovoCare or Ro.
It’s for adults who already tolerated Wegovy 2.4 mg for at least 4 weeks and need more weight loss. Don’t expect to start at 7.2 mg — the dose escalation is part of the label.
Are Compounded GLP-1s a Substitute for an FDA-Approved One on MedImpact?
No — and not for the reason you might think.
This page is specifically about FDA-approved GLP-1s on MedImpact’s formulary because compounded GLP-1s are an entirely different category. They’re not FDA-approved finished products. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they’re marketed.
For this search — best FDA-approved GLP-1 on the MedImpact formulary — the answer stays within FDA-approved branded medications: Mounjaro, Ozempic, Rybelsus, Trulicity, Wegovy (pen and pill), Zepbound, Foundayo, Wegovy HD, and Saxenda. If your MedImpact plan denies coverage and you want a compounded GLP-1 instead, we’d send you to a different guide.
How MedImpact Compares to Other PBMs for GLP-1 Coverage
MedImpact is one of several major pharmacy benefit managers (CVS Caremark, Express Scripts, OptumRx are the others). All treat diabetes GLP-1s and weight-loss GLP-1s as separate coverage categories. All require prior authorization. What sets MedImpact apart in 2026 is the GLP-1 Benefit 360 and GLP-1 Direct Fund programs — structured employer options that didn’t exist before.
| MedImpact-specific feature | Why it matters | What to ask HR or member services |
|---|---|---|
| GLP-1 Benefit 360 | Capped plan and member spend; same price across doses; bundled coaching + app | “Does my plan participate in GLP-1 Benefit 360?” |
| GLP-1 Direct Fund | Employer contributes toward DTC pricing when plan doesn’t cover GLP-1s outright | “Does my plan offer the GLP-1 Direct Fund employer contribution?” |
| MedEmpower Fuel app | Free coaching and lifestyle support for Benefit 360 members | “Do I have access to MedEmpower Fuel?” |
| Anti-Obesity Agents category (Jan 2026 full formulary) | Wegovy and Zepbound listed as Tier 2 PA/QL when employer opts in | “Did my employer opt into anti-obesity drug coverage?” |
| Weight Reduction category (April 2026 PDL) | Same drugs, newer document, same opt-in question | “Is my plan running on the January or April formulary version?” |
How To Decide: Doctor, Portal, Ro, or Sesame?
| Starting Point | Best For | Not Best For | Next Step |
|---|---|---|---|
| MedImpact portal/app | Verifying your specific formulary, tier, PA, and copay | Getting a prescription | Search Wegovy / Zepbound / Mounjaro / Ozempic |
| Your existing doctor | Complex history, T2D, CKD/CVD, long-term continuity | When you can’t get timely PA support | Bring the doctor script from above |
| Ro Body | Brand-name FDA-approved GLP-1 + Insurance Concierge for commercial plans | Medicaid members; Medicare insurance routing | Check eligibility — $39 first month |
| Sesame Care | Provider choice, transparent branded GLP-1 menu | One integrated concierge experience | Compare Sesame’s GLP-1 providers |
Provider-stated vs. verified: Ro and Sesame
| Provider | Provider-stated feature | What we verified | Caveat | Best fit |
|---|---|---|---|---|
| Ro Body | Insurance Concierge for FDA-approved GLP-1s | Submits PA paperwork, goes back and forth with insurance, explores alternatives if coverage fails | Can’t coordinate government coverage; Medicaid members cannot join at all | Commercial MedImpact members who want hands-off PA support |
| Ro Body | $39 first month, $149/mo ongoing | Confirmed; or as low as $74/mo with annual prepay | Membership is separate from medication cost | Members willing to pay membership for service depth |
| Ro Body | FDA-approved GLP-1 menu | Includes Foundayo, Wegovy pill, Wegovy pen, Zepbound pen, Zepbound KwikPen, Zepbound vials, Ozempic | Lineup varies by state | Anyone who specifically wants brand-name medication |
| Sesame Care | $59/mo subscription (annual) | Confirmed | Medication price is separate from subscription | Members who want lower service fee + provider choice |
| Sesame Care | Providers handle PA paperwork | Sesame says providers can work directly with insurance to handle PA for weight-loss medication | PA outcome depends on plan rules | Members who already know their plan covers GLP-1s |
| Sesame Care | Wegovy pill, Zepbound, Foundayo, Ozempic, Mounjaro, Saxenda | Confirmed menu | Pricing varies by drug and dose | Members who want to compare branded options |
Why Ro is our primary recommendation for MedImpact members
Ro’s Insurance Concierge contacts your insurance, submits the PA paperwork, goes back and forth with the plan, and explores alternatives or cash-pay if the first option fails — all included in the Ro Body membership. The medication is billed through your MedImpact pharmacy benefit at your normal copay if approved. Ro carries the broadest FDA-approved GLP-1 menu currently available through a single concierge workflow.
MedImpact commercial member? Check eligibility on Ro → (sponsored affiliate link, opens in a new tab)(sponsored)Why Sesame Care is the secondary recommendation
Sesame offers a branded GLP-1 menu including Wegovy, Zepbound, Foundayo, Ozempic, Mounjaro, and Saxenda. You pick your clinician. Subscription pricing starts as low as $59/month annually. It’s especially strong if you want Costco-member pricing on Wegovy or Ozempic.
Compare Sesame Care’s GLP-1 providers → (sponsored affiliate link, opens in a new tab)(sponsored)Honest Tradeoffs and What MedImpact’s Formulary Doesn’t Tell You
The fine print, in one place
- ›MedImpact administers; your employer decides. The standard formulary and PDL are defaults. Your employer chose the actual coverage on top of them.
- ›PA timing. Ro says its GLP-1 PA process typically takes 2–3 weeks and can take longer if more documentation is needed. Don’t book your start date based on next week.
- ›Mid-year formulary changes. Drugs can move tiers or come off the formulary entirely with notice. The drug you got approved for in January might need re-authorization later if your plan changes.
- ›Specialty pharmacy and Birdi mail order. Some MedImpact plans require certain GLP-1s to be dispensed by a specialty pharmacy or through Birdi (MedImpact’s mail-order pharmacy). Your portal will tell you if this applies.
- ›Manufacturer copay cards have limits. They typically require commercial insurance, exclude government insurance, set maximum savings caps, and expire on program-specific dates.
- ›The cash-pay floor is still real. $149/month for the lowest doses of Wegovy pill or Foundayo isn’t nothing. Plan for it before you start.
Frequently Asked Questions
Does MedImpact cover Mounjaro?
Yes. Mounjaro is a preferred-brand GLP-1 on MedImpact’s January 2026 MedPerform Premier formulary for type 2 diabetes — Tier 2 with prior authorization, diagnosis-code requirement, and a quantity limit of 0.5 mL per 7 days. Coverage for weight loss is generally NOT available because Mounjaro is FDA-approved for T2D, not chronic weight management — its weight-loss counterpart is Zepbound (same active ingredient, different brand and indication).
Does MedImpact cover Wegovy for weight loss?
Wegovy is listed as a preferred brand under MedImpact’s anti-obesity category (Anti-Obesity Agents in the January full formulary; Weight Reduction in the April PDL). The “if covered” caveat means your employer’s plan had to opt into anti-obesity drug coverage for Wegovy to actually be paid. Call your member services number to confirm whether your plan opted in.
Does MedImpact cover Zepbound?
Same situation as Wegovy. Zepbound is listed as preferred brand under the anti-obesity / weight reduction category. Coverage depends on whether your plan opted into anti-obesity drug coverage. Search “Zepbound” in your MedImpact portal — if you see a tier and estimated copay, that’s a strong signal, but you still need to confirm PA, diagnosis, quantity-limit, pharmacy, and benefit rules before assuming the claim will pay.
Does MedImpact cover Ozempic for weight loss?
No, generally not. Ozempic is FDA-approved for type 2 diabetes and for reducing major adverse cardiovascular events in adults with T2D and established cardiovascular disease. MedImpact covers it for those indications. Prescribing Ozempic off-label for weight loss isn’t typically covered. If weight management is your goal, you want Wegovy (same active ingredient, semaglutide, but FDA-approved for weight loss).
Why does MedImpact show Tier 2 but still deny my claim?
Tier and copay are only one piece of coverage. A drug can show Tier 2 and still be denied because of PA criteria, diagnosis mismatch, quantity limits, pharmacy network requirements, or benefit exclusions. Ask your plan to identify which one is causing the block — then use the action table on this page to take the right next step.
What does PA mean on a MedImpact GLP-1?
PA means prior authorization. Your prescriber sends MedImpact a Medication Request Form with supporting documentation (diagnosis, clinical history, prior medication trials). MedImpact reviews it against the plan’s clinical criteria. Until PA is approved, the pharmacy won’t dispense the drug under your benefit.
What does QL mean on a MedImpact GLP-1?
QL means quantity limit. It caps how much medication you can get in a defined period. The January 2026 MedImpact full formulary lists specific QLs: Ozempic is 3 mL per 28 days, Trulicity is 2 mL per 28 days, Mounjaro is 0.5 mL per 7 days, Rybelsus is 1 tablet per day. If you escalate to a higher dose, the QL math changes — ask your prescriber and pharmacy to confirm the refill cadence.
Is Foundayo on the MedImpact formulary?
Not as of the public January or April 2026 MedImpact MedPerform Premier formularies we reviewed. Foundayo was FDA-approved on April 1, 2026. Expect MedImpact to update through 2026. Until then, file a formulary exception or use Foundayo’s self-pay program ($149–$349/month depending on dose) or the Foundayo Savings Card with qualifying commercial insurance.
Is Wegovy HD on the MedImpact formulary?
Not as of the public January or April 2026 PDL. Wegovy HD (semaglutide 7.2 mg) was FDA-approved March 19, 2026 and launched in April 2026. Coverage will follow quarterly formulary refreshes. Self-pay is $399/month.
What is the MedImpact prior authorization process for GLP-1?
Your doctor submits a Medication Request Form to MedImpact with supporting documentation. For T2D drugs: confirmed diagnosis with A1C, often a documented metformin trial unless contraindicated, and sometimes step therapy. For weight-management drugs (when covered): BMI of 30+ (or 27+ with a weight-related condition), documentation of lifestyle modification, and prior weight-loss attempts. PA timing varies; Ro says its GLP-1 PA process typically takes 2–3 weeks.
What is MedImpact GLP-1 Benefit 360?
A new program MedImpact launched on March 24, 2026. It’s a structured covered-benefit option that employers can adopt. Key features: capped plan and member spending, consistent pricing across all dose strengths, and integrated MedEmpower Fuel app plus registered dietitian coaching. If your employer adopted it, your coverage is more predictable than a standard plan.
What is MedImpact GLP-1 Direct Fund?
Also launched March 24, 2026. It’s a flexible alternative for employers who don’t offer a traditional covered GLP-1 benefit. The plan contributes a set dollar amount toward direct-to-consumer pricing (like LillyDirect, NovoCare, or Ro).
What if my GLP-1 prior authorization is denied?
Ask for the denial reason in writing — it’s required by law. Then identify which of the three denial types you’re dealing with: missing documentation, non-formulary, or benefit exclusion. Each has a different next step. Missing documentation can usually be fixed by resubmitting. Non-formulary can be appealed via a formulary exception. Benefit exclusion is the hardest — appeals rarely succeed, and your practical options are cash-pay or waiting for plan changes.
Can I use my MedImpact insurance with Ro?
The Ro Body membership fee ($39 first month, then $149/month or as low as $74/month with annual prepay) is paid out of pocket. The medication itself is billed through your MedImpact pharmacy benefit at your normal copay if PA is approved. If you’re paying cash, Ro matches LillyDirect, NovoCare, and TrumpRx pricing.
Does Ro work with Medicare or Medicaid?
Ro cannot coordinate GLP-1 insurance coverage for government insurance. Medicare, Medicare supplement, and TRICARE members can still join Ro Body and pay out of pocket for certain cash-pay options. Medicaid and other government-funded insurance members cannot join Ro Body at all. FEHB members can join Ro Body and access the Insurance Concierge.
What’s the difference between MedImpact and my insurance company?
MedImpact is the pharmacy benefit manager (PBM). They administer the pharmacy portion of your benefits. Your insurance company (or self-insured employer) contracts with MedImpact. The MedImpact formulary and PDL are defaults; your specific plan sponsor customizes what’s actually covered on top of them.
Are compounded GLP-1s a substitute for FDA-approved Wegovy on MedImpact?
No. Compounded medications are not FDA-approved finished products, and they’re not covered by MedImpact insurance the way branded FDA-approved drugs are. They’re an entirely separate category with their own pricing and access models. If your goal is FDA-approved medication on your insurance, compounded isn’t the same thing.
Still Not Sure Which GLP-1 Is Right for You?
You’ve got the formulary read. You’ve got the doctor script. You’ve got the phone script and the cash-pay fallback. But there’s one more variable that matters more than any formulary row: you.
Take our free 60-second matching quiz.
We’ll route you to your best FDA-approved option with the exact next step — whether that’s pursuing PA through your MedImpact plan, going straight to Ro Body for Insurance Concierge support, or picking your own clinician on Sesame Care.
Start the free 60-second match →Methodology
The data on this page comes from the January 2026 MedImpact MedPerform Premier Standard Formulary and the April 1, 2026 MedImpact MedPerform Premier PDL update. We use the January full formulary for detailed PA, QL, and step-therapy notes, and the April PDL to confirm the most recent public preferred-drug listings. We cross-referenced both against MedImpact’s March 24, 2026 announcement of GLP-1 Benefit 360 and GLP-1 Direct Fund, and verified all pricing claims against Ro, LillyDirect, NovoCare, and Sesame Care as of May 2026.
We did NOT use Reddit threads, forums, or anecdotal posts as medical or coverage evidence. We did NOT add fake reviewer credentials or “medically reviewed by” badges. This page is updated quarterly and immediately after any major FDA approval, MedImpact formulary refresh, or manufacturer price change.
Related guides on The RX Index
- Best GLP-1 Providers That Accept Insurance
- Best Brand-Name GLP-1 Telehealth Providers
- GLP-1 Providers That Accept Cigna
- Does Insurance Cover GLP-1 for High Blood Pressure?
- Does Insurance Cover GLP-1 for Prediabetes?
- Best GLP-1 for Diabetes
- Wegovy Pill Providers That Accept Insurance
- GLP-1 Cost Without Insurance
- GLP-1 Prior Authorization Help: Best Providers
Page sources
- • MedImpact Healthcare Systems. MedPerform Premier Standard Formulary, January 2026.
- • MedImpact Healthcare Systems. MedPerform Premier Preferred Drug List update, April 1, 2026.
- • MedImpact Healthcare Systems. MedImpact Redefines Obesity Care with New Suite of GLP-1 Solutions. Press release, March 24, 2026.
- • FDA / DailyMed prescribing information for Mounjaro, Ozempic, Trulicity, Rybelsus, Wegovy, Zepbound, Foundayo, Saxenda.
- • Eli Lilly. Foundayo (orforglipron) Prescribing Information and Coverage & Savings, April 2026.
- • Novo Nordisk. Wegovy HD (semaglutide 7.2 mg) FDA approval announcement, March 19, 2026.
- • Ro. Weight Loss Program Pricing and Insurance Pages, ro.co. Verified May 2026.
- • Sesame Care. Online Weight Loss Program, sesamecare.com. Verified May 2026.
- • CMS. Medicare GLP-1 Bridge. cms.gov.
Last verified: May 23, 2026 · Next verification: August 2026 · Updated quarterly and immediately after any major FDA approval, MedImpact formulary refresh, or manufacturer price change.
Affiliate disclosure: The RX Index may earn a commission when readers sign up for services through links on this page, at no additional cost to the reader. This does not influence which providers we recommend.